Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that its New Drug Application (NDA) for oxybutynin chloride topical gel (OTG), has been accepted for filing by the U.S. Food and Drug Administration (FDA). Watson is seeking marketing approval of this novel transdermal gel of oxybutynin hydrochloride for the treatment of overactive bladder (OAB).
The details can be read here.
No comments:
Post a Comment